Navigation Links
GenVec to Present at the 13th Annual BIO CEO & Investor Conference
Date:2/8/2011

GAITHERSBURG, Md., Feb. 8, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq:  GNVC) today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a company overview highlighting recent developments at the 13th Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011 at 2:30 p.m. EST at the Waldorf Astoria Hotel in New York City.

A webcast of Dr. Fischer's presentation will be available both live and on replay.  To access either the live or archived webcast, log on to GenVec's website at www.genvec.com, click on "Investor Relations," and proceed to "Webcasts & Data."  The replay will be available 3 hours after the live presentation and will be accessible for 30 days.

About GenVecGenVec, Inc. is a biopharmaceutical company using superior, proprietary technology to create differentiated vaccines and therapeutics that are developed and commercialized through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the US Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), HSV-2, dengue fever, influenza, HIV, malaria, and foot-and-mouth disease. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.Investor and Media Contact: GenVec, Inc. Douglas J. Swirsky (240) 632-5510 dswirsky@genvec.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
2. GenVec Reports Third Quarter 2009 Financial Results
3. GenVec Announces Third Quarter 2009 Results Conference Call
4. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
5. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
6. GenVec Reports Second Quarter 2009 Financial Results
7. GenVec Expands Contract Supporting Malaria Vaccine Program
8. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
9. Lexicon Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference
10. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
11. Mosaic to Present at Goldman Sachs Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses ... EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The ...
(Date:10/6/2017)... Boston, Mass. (PRWEB) , ... October 06, 2017 ... ... spotlight female entrepreneurship within the healthcare and technology sector at their fourth annual ... six panels featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):